SNY Stock Analysis & IQ Rating | Sanofi

SNY Price Performance

SNY Analysts opinion is positive and also has improved from the past 3 months

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Today

Sanofi Wins EU Approval For Teizeild In Stage 2 Type 1 Diabetes . (RTTNews) - Sanofi (SNY) announced that the European Commission has approved Teizeild for adult and pediatric patients aged eight years and older with stage 2 type 1 diabetes.

Today

Sanofi (SNY) Reports Regulatory Win Barclays Downgrades to Equal Weight with EUR 85 PT. Sanofi (NASDAQ:SNY) is one of the most undervalued blue chip stocks to buy now. On January 6 2026 Barclays downgraded Sanofi (NASDAQ:SNY) from Overweight to Equal Weight while setting an EUR 85 price target. The firms update reflects its more cautious long-term outlook on the company despite the strong operational outlook and an undemanding valuation. [….]

Today

Press Release: Sanofis Teizeild approved in the EU for patients with stage 2 type 1 diabetes. Sanofi'.s Teizeild approved in the EU for patients with stage 2 type 1 diabetesApproval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patientsTeizeild represents a potential significant change in the treatment of autoimmune T1D preventing the natural disease progression protecting beta-cell functionParis January 12 2026. The European Co

Today

CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery. This marks CytoReasons fifth commercial deal of 2025 and builds on its track record with half of the worlds top twenty pharma companies which have leveraged its technology across a range of programs. TEL AVIV Israel Jan. 9 2026 /PRNewswire/ -- CytoReason a leader in AI-powered...

Fri Jan 9, 2026

Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying Clustering Antibody Pipeline. Financing co-led by Sanofi Ventures and Janus Henderson Investors with participation from new investors Deep Track Capital EcoR1 Capital Logos Capital Balyasny Asset Management L.P. Woodline Partners LP and all existing investorsProceeds to fund clinical development of DIAG723 a first-in-class disease-modifying therapy designed to corre

Thu Jan 8, 2026

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases. Financing supports Phase 2 development of ALV-100 IND filing of ALV-200 and advancement of additional programs across the R&.D pipelineALV-100 a bifunctional GIPR antagonist / GLP-1R agonist designed for durable weight management with improved quality of weight loss and long-term maintenance Differentiated amylin-based pipeline including an AMYR3 peptide a

Thu Jan 8, 2026

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities. CINCINNATI Jan. 06 2026 (GLOBE NEWSWIRE) -- (Enable) a healthcare innovation company developing and manufacturing the enFuse®. On-Body Delivery System (OBDS) announced today that Sanofi is making a $30 million investment to accelerate Enable'.s manufacturing build-out strengthen its supply chain capabilities and drive commercial growth.This investment from one of our key partners show

Tue Jan 6, 2026

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children. Sanofi wins FDA priority review to expand Tzields use to children as young as one aiming to delay type 1 diabetes progression.

Mon Jan 5, 2026

Earendil Labs Announces Strategic Collaboration with Sanofi to Discover Bispecific Antibodies for Autoimmune Diseases. WILMINGTON Del. Jan. 5 2026 /PRNewswire/ -- Earendil Labs a global leader in AI-driven research and development of next-generation biologics therapeutics today announced a strategic collaboration with Sanofi to apply Earendils discovery platform to multiple autoimmune and...

Mon Jan 5, 2026